[ET Net News Agency, 28 August 2025]  CSPC PHARMA (01093) fell 3% to HK$9.43. 
  It hits an intra-day low of HK$9.42, and an intra-day high of HK$9.87. The total shares 
traded was 85.6 million, with a value of HK$817.85m. The active buy/sell ratio is 46:54,  
with net selling turnover of HK$64.65m. J.P. MORGAN BRO (HK) accounts for greatest net  
responsive buying turnover of HK$48.25m, with volume weighted average price of HK$9.54. 
CHINA INNOVATION MARKET SER accounts for greatest net responsive selling turnover of  
HK$48.23m, with volume weighted average price of HK$9.535. The stock has fallen a combined
13.1% over the past 3 consecutive trading days. 
  The Hang Seng Index now fell 180 points, or 0.7% to 25,021; the Hang Seng China 
Enterprises Index now fell 75 points, or 0.8% to 8,944. 
  
          Basic Information 
          ================= 
  
  ----------------------------------
  Nominal    9.430 % Chg     -2.98% 
  High       9.870 Low        9.420 
  Shares Tr  85.6m Turnover 817.85m 
  10-D SMA  10.424 %H.V      56.014 
  20-D SMA  10.268 VWAP       9.554 
  50-D SMA   9.152 RSI14     43.728 
  ----------------------------------
Status: Active buy/sell ratio is 46:54, with net selling turnover of HK$64.65m, falling a 
combined 13.1% over the past 3 consecutive trading days 
  
Performance of stocks in the same sector or of relevance
========================================================
  
  Stock (Code)            Price (HK$) Change (%)
  ----------------------------------------------- 
  CSPC PHARMA (01093)            9.43      -2.98
  SINOPHARM (01099)             18.75      -0.79
  SINO BIOPHARM (01177)          7.72      -2.40
  INNOVENT BIO (01801)          90.50      -0.55
  WUXI BIO (02269)              30.74      -3.21
  WUXI APPTEC (02359)          100.30      -1.67
  CHINARES PHARMA (03320)        4.92      -1.80
  HANSOH PHARMA (03692)         35.40      -0.34
  BEIGENE (06160)              175.20      -1.96
  AKESO (09926)                151.10      -3.76
  ----------------------------------------------- 
  (ed)



 
 